Suppr超能文献

一名前列腺癌患者在药物去势及后续手术去势后睾酮抑制不足。

Inadequate testosterone suppression after medical and subsequent surgical castration in a patient with prostate cancer.

作者信息

Ragnarsson Oskar, Johannsson Gudmundur, Geterud Kjell, Lodding Par, Dahlqvist Per

机构信息

Department of Endocrinology, Diabetes and Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden.

出版信息

BMJ Case Rep. 2013 Aug 13;2013:bcr2013010395. doi: 10.1136/bcr-2013-010395.

Abstract

Androgen deprivation is a cornerstone in prostate cancer management. We present a 69-year-old man, with a poorly differentiated prostate cancer with skeletal and lymph node metastases. After medical and subsequent surgical castration serum testosterone concentrations remained inappropriately high (4.9 and 4.5 nmol/L; castration range < 0.5). For cancer staging a CT was performed which showed bilateral adrenal enlargement. Endocrine workup revealed elevated levels of adrenal androgens and adrenal precursors. Mutation analysis confirmed a non-classical 21-hydroxylase deficiency, that is, a mild form of congenital adrenal hyperplasia (CAH). To suppress adrenocorticotrophic hormone and the excess adrenal androgen secretion, treatment with hydrocortisone and prednisolone was started with success. Inadequate testosterone suppression after castration due to previously undiagnosed CAH has not previously been reported. Considering the estimated prevalence of 1% in selected populations, non-classical CAH should be considered when testosterone is not adequately suppressed after castration in men with prostate cancer.

摘要

雄激素剥夺是前列腺癌治疗的基石。我们报告一名69岁男性,患有低分化前列腺癌并伴有骨骼和淋巴结转移。在药物去势及随后的手术去势后,血清睾酮浓度仍异常升高(分别为4.9和4.5 nmol/L;去势范围<0.5)。为进行癌症分期,行CT检查显示双侧肾上腺增大。内分泌检查发现肾上腺雄激素和肾上腺前体水平升高。突变分析证实为非经典型21-羟化酶缺乏,即先天性肾上腺皮质增生症(CAH)的一种轻度形式。为抑制促肾上腺皮质激素及过量肾上腺雄激素分泌,开始使用氢化可的松和泼尼松龙治疗并取得成功。此前尚未报道过因既往未诊断的CAH导致去势后睾酮抑制不足的情况。考虑到特定人群中估计患病率为1%,对于前列腺癌男性患者去势后睾酮未得到充分抑制时,应考虑非经典型CAH。

相似文献

8
Hormonal therapy of prostate cancer.前列腺癌的激素治疗。
Prog Brain Res. 2010;182:321-41. doi: 10.1016/S0079-6123(10)82014-X.

本文引用的文献

2
Testosterone in prostate cancer: the Bethesda consensus.前列腺癌中的睾酮:贝塞斯达共识。
BJU Int. 2012 Aug;110(3):344-52. doi: 10.1111/j.1464-410X.2011.10719.x. Epub 2011 Nov 30.
3
Incomplete testosterone suppression in prostate cancer.前列腺癌中睾酮抑制不完全。
N Engl J Med. 2010 Nov 11;363(20):1976. doi: 10.1056/NEJMc1010187.
5
Testosterone measurement in patients with prostate cancer.前列腺癌患者的睾酮测量。
Eur Urol. 2010 Jul;58(1):65-74. doi: 10.1016/j.eururo.2010.04.001.
8
Extensive clinical experience: nonclassical 21-hydroxylase deficiency.丰富的临床经验:非经典型21-羟化酶缺乏症
J Clin Endocrinol Metab. 2006 Nov;91(11):4205-14. doi: 10.1210/jc.2006-1645. Epub 2006 Aug 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验